Stocks Health care IBIO
NASDAQ · Health careiBio, Inc. (IBIO)
iBio, Inc. reported revenue of $100K in fiscal 2026, down 75.0% from a year earlier. It posted a net loss of $33M. In fiscal 2026 capital spending exceeded operating cash flow by $23.8M. At June 30, 2026 it held $56.4M in cash. Its latest periodic report to the SEC is the annual report (10-K) filed on August 28, 2026.
Key facts about iBio, Inc.
- Net worth
- iBio, Inc. has a market value (market cap) of $38.6M at the latest share price, and shareholders' equity of $85.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2026 revenue was $100K (-75.0% year on year), with a net loss of $33M.
- Cash flow
- In fiscal 2026 operations used $23.2M of cash.
- Latest report
- The latest periodic report (annual report, 10-K) was filed with the SEC on August 28, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- iBio, Inc.'s next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What iBio, Inc. does
iBio, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker IBIO.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2026 | $100K | -$33M | -$0.32 | -$23.8M |
| 2025 | $400K | -$18.4M | -$1.75 | -$15.3M |
| 2024 | $225K | -$24.9M | -$6.50 | -$18.8M |
| 2023 | $0 | -$65M | -$106.19 | -$36.2M |
| 2022 | $1.9M | -$50.3M | -$115.59 | -$44.8M |
| 2021 | $2.4M | -$23.2M | -$59.99 | -$35M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where IBIO ranks in Health care
Latest SEC filings
What iBio, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 14, 2026
- September 4, 2026
- September 4, 2026Proxy statement DEF 14A
- August 28, 2026Annual report 10-K · period to June 30, 2026Revenue fell 75% to $100K versus the prior year; diluted EPS -$0.32 versus -$1.75.
- August 28, 2026
- August 20, 2026Preliminary proxy statement PRE 14A
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026Passive stake changed SCHEDULE 13G/A
Insider trades
What the people running iBio, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| March 26, 2026 | Banjak MarcChief Legal Officer | Bought | 12,500 | $20.5K |
| March 26, 2026 | Banjak MarcChief Legal Officer | Bought | 1,434 | $2.5K |
| March 19, 2026 | Brenner MartinSee Remarks, Director | Bought | 12,336 | $24.9K |
| March 19, 2026 | Duran FelipeChief Financial Officer | Bought | 24,835 | $50.1K |
Who owns IBIO
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Adage Capital Management, L.P.13G, passive with 2 related filers | 9.99% | November 13, 2025 |
| Affinity Asset Advisors, LLC13G, passive with 1 related filers | 9.99% | August 13, 2026 |
| Cormorant Asset Management, LP13G, passive with 1 related filers | 9.99% | August 14, 2026 |
| SilverArc Capital Management, LLC13G, passive with 2 related filers | 9.99% | November 14, 2025 |
| Sirenia Capital Management LP13G, passive with 1 related filers | 9.9% | May 15, 2026 |
| Vestal Point Capital, LP13G, passive with 1 related filers | 7.9% | August 14, 2026 |
| Opaleye Management, Inc.13G, passive | 7.6% | February 14, 2025 |
| Frazier Life Sciences Public Fund, L.P.13G, passive with 8 related filers | 5.7% | May 12, 2026 |
| Lynx1 Capital Management LP13G, passive with 1 related filers | 5.4% | August 14, 2026 |
| Millennium Management LLC13G, passive with 3 related filers | 5.2% | January 22, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 55 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Affinity Asset Advisors, LLC | 4,007,881 | +900,681 |
| Cormorant Asset Management, LP | 3,570,000 | new |
| Silverarc Capital Management, LLC | 3,520,490 | +3,294,490 |
| Vestal Point Capital, LP | 2,600,000 | new |
| Vanguard Capital Management LLC | 2,098,151 | +1,009,852 |
| Frazier Life Sciences Management, L.P. | 1,953,467 | 0 |
| Ensign Peak Advisors, Inc | 1,832,457 | new |
| Woodline Partners LP | 1,776,547 | new |
| Millennium Management LLC | 1,651,473 | +101,623 |
| Citadel Advisors LLC | 1,384,029 | +427,600 |
| Balyasny Asset Management L.P. | 1,170,893 | +159,938 |
| Bank of America Corp | 1,121,492 | +831,079 |
| Ikarian Capital, LLC | 957,062 | 0 |
| Sio Capital Management, LLC | 904,268 | 0 |
| Marshall Wace, Llp | 904,132 | +283,530 |
| Geode Capital Management, LLC | 500,816 | +113,249 |
| Walleye Capital LLC | 500,375 | +111,821 |
| Squarepoint Ops LLC | 498,872 | new |
| Noesis Capital Mangement Corp | 405,000 | +93,500 |
| Two Sigma Investments, LP | 400,667 | -8,191 |
Insiders
3 insiders reported holding 91,626 shares in total, about $71.1K at the last price.
| Holder | Shares |
|---|---|
| Duran FelipeChief Financial Officer | 35,974 |
| Brenner MartinSee Remarks, Director | 30,652 |
| Banjak MarcChief Legal Officer | 25,000 |
Questions about IBIO
What does iBio, Inc. do?
iBio, Inc. is a company in the Health care sector, listed on NASDAQ as IBIO. Its shares trade on NASDAQ under the ticker IBIO.
What is iBio, Inc.'s net worth?
iBio, Inc. has a market value (market cap) of $38.6M at the latest share price, and shareholders' equity of $85.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is iBio, Inc. profitable?
No. In fiscal 2026 it reported a net loss of $33M on revenue of $100K.
How much revenue does iBio, Inc. make?
In fiscal 2026 iBio, Inc. reported revenue of $100K. That is 75.0% less than a year earlier.
When did iBio, Inc. last report?
Its most recent periodic report is the annual report (10-K) filed on August 28, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the investor disclosure from September 14, 2026.
When is iBio, Inc.'s next earnings report?
iBio, Inc.'s next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare IBIO with
Follow IBIO
Get an email when iBio, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values iBio, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.